Immuneering Corporation provided a positive update on January 13, 2025, regarding its Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) for first-line pancreatic cancer. The company reported two new partial responses (PRs) in this arm, contributing to an Overall Response Rate (ORR) of 50%.
This ORR of 50% compares to a historic benchmark of 32% for FOLFIRINOX alone, indicating enhanced efficacy. The data reinforces the potential of IMM-1-104 to improve outcomes in this difficult-to-treat patient population.
In addition to the clinical update, Immuneering announced that it raised nearly $14 million in net proceeds during January 2025 through the utilization of its At-The-Market (ATM) facility. This capital infusion provides additional financial resources to support ongoing clinical development and operations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.